{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-002216","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.987983+00:00","generated_at":"2026-06-10T04:12:31.464967+00:00","sec_items":["2.01","1.01","2.03","3.02","9.01","3.01","3.03","5.03","5.01","5.02","5.05","5.06"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TradeUP Acquisition Corp completes merger with Estrella Biopharma; becomes Estrella Immunopharma, listing on Nasdaq","bullets":["Merger consideration of $325M; Estrella stockholders receive 32.5M shares; name changes to Estrella Immunopharma.","Gross proceeds of ~$23.11M from PIPE ($10M) and Series A sales ($9.75M); funds expected to support operations into 2024.","Officers/directors own ~92.3% of outstanding shares; former UPTD holders own ~4.8%.","Common stock (ESLA) and warrants (ESLAW) start trading on Nasdaq on Oct 2, 2023.","Entered into $50M equity line with White Lion Capital; 3.5M shares authorized under 2023 Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-002216","json":"https://secwatch.observer/filing/0001013762-23-002216.json","markdown":"https://secwatch.observer/filing/0001013762-23-002216.md","text":"https://secwatch.observer/filing/0001013762-23-002216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/ea185637-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:12:31.464967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09859156aa796fce1e5280e87ec73ed0d3c184ea","claim":"Estrella Immunopharma, Inc.: New amended and restated bylaws (New Bylaws) approved and adopted by board of directors, effective as of the Effective Time (September 29, 2023) (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, the board of directors of New Estrella approved and adopted the New Bylaws, which became effective as of the Effective Time.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"governance_change"},{"claim_id":"59ae6937b7a16134cf828840b9a9411441dd194a","claim":"Estrella Immunopharma, Inc.: Board of directors approved and adopted a new Code of Ethics applicable to directors, officers and employees in connection with the Closing (effective 2023-09-29).","evidence_excerpt":"In connection with the Closing, the board of directors of New Estrella approved and adopted a new Code of Ethics applicable to directors, officers and employees.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"governance_change"},{"claim_id":"93557e51e357a6e32ab9eda7c41a5db984fda77e","claim":"Estrella Immunopharma, Inc.: Amended and restated certificate of incorporation (New Charter) approved at special meeting and effective upon filing with Secretary of State of Delaware on September 29, 2023 (effective 2023-09-29).","evidence_excerpt":"The New Charter, which became effective upon filing with the Secretary of State of the State of Delaware on September 29, 2023, includes the amendments proposed by the Charter Proposal and approved at the Special Meeting.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"governance_change"},{"claim_id":"a9a40591f2e213a64e11a11625ec7185f59cc8a9","claim":"Estrella Immunopharma, Inc.: Upon the Closing, New Estrella ceased to be a shell company.","evidence_excerpt":"Upon the Closing, New Estrella ceased to be a shell company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"b28c27dfaaf1015d633e9090e024d85515463c61","claim":"Estrella Immunopharma, Inc. underwent a change of control involving TradeUP Acquisition Corp. for $325,000,000 (closed 2023-09-29).","evidence_excerpt":"from UPTD, in the aggregate, a number of newly issued shares of common stock of New Estrella (as defined below), par value $0.0001 per share (“Common Stock”) equal to: (i) $325,000,000 (the “Merger Consideration”), divided by (ii) $10.00 per share (such shares of Common Stock is referred as “Merger Consideration Shares”) in consideration of converting their","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000101376223002216/0001013762-23-002216-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"TradeUP Acquisition Corp."},{"label":"Consideration","value":"$325,000,000"},{"label":"Closing","value":"2023-09-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}